Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02371967
- Locations
- 🇸🇪
Skånes Universitetssjukhus; Hudkliniken, Lund, Sweden
🇸🇪SU/Sahlgrenska, Hudkliniken, Göteborg, Sweden
🇸🇪Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1021
- Registration Number
- NCT02367794
- Locations
- 🇺🇸
Southern CA Permanente Med Grp, Bellflower, California, United States
🇺🇸Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente - Santa Clara, Santa Clara, California, United States
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Squamous Non-Small Cell Lung
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 723
- Registration Number
- NCT02367781
- Locations
- 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1202
- Registration Number
- NCT02366143
- Locations
- 🇺🇸
Piedmont Cancer Institute, PC, Atlanta, Georgia, United States
🇺🇸Univ of Pittsburgh Medical Ctr, Pittsburgh, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02350673
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇺🇸SCRI-Tennessee Oncology, Nashville, Tennessee, United States
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02342925
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 631
- Registration Number
- NCT02340221
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria
🇧🇬Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 212
- Registration Number
- NCT02340234
- Locations
- 🇨🇦
The Centre for Dermatology, Richmond Hill, Ontario, Canada
🇩🇪Universitätsklinik Bonn, Bonn, Germany
🇫🇮Helsinki University Central Hospital; Skin & Allergy Hospital, Helsinki, Finland
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02336048
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT02324257
- Locations
- 🇺🇸
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇪🇸START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇺🇸Stanford University, Palo Alto, California, United States